Skip to content
About
Introduction
Community commitment
Senior Leadership
Board of Directors
Science
Publications and relevant literature
Pipeline
ANB033
Overview
Celiac Disease
Eosinophilic Esophagitis
Rosnilimab
ANB101
Patients & Families
Investors/Media
News & events
News releases
Events
Presentations
Stock
Stock quote & chart
Historical price lookup
Analyts coverage
Governance
Documents & charters
Senior Leadership
Board of Directors
Committee composition
Financials
SEC filings
IR resources
Investor FAQs
Email alerts
Information request
Contact us
Careers
Contact us
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Go to Top
Clear
Search
About
Introduction
Community commitment
Senior Leadership
Board of Directors
Science
Publications and relevant literature
Pipeline
ANB033
Overview
Celiac Disease
Eosinophilic Esophagitis
Rosnilimab
ANB101
Patients & Families
Investors/Media
News & events
News releases
Events
Presentations
Stock
Stock quote & chart
Historical price lookup
Analyts coverage
Governance
Documents & charters
Senior Leadership
Board of Directors
Committee composition
Financials
SEC filings
IR resources
Investor FAQs
Email alerts
Information request
Contact us
Careers
Contact us
